arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

CERUS CORP

CERS
$2.34 ▲ +0.02 (+1.08%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
18 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

CERUS CORP faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $446.0M
Dividend Yield
Revenue Growth 16.1%
Op. Margin -3.7%
ROIC -13.8%
FCF / Share $0.01
Trailing P/E
Price / Book 7.0x
FCF Yield 0.3%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$233.80M
↑ +16.1%
Net Income Profit after all expenses
$-15.63M
↑ +25.3%
Operating Margin Operating profit as % of sales
-3.7%
↑ +47.5% 21th
FCF / Share Free cash flow per share
$0.01
↓ -87.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
22
Returns
26
Financial Health
45
Cash Quality
20

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters